Jnana Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
90
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$800M
Jnana Therapeutics General Information
Description
Developer of a drug discovery platform designed to target the solute carrier family of transporters and cell's metabolic gates. The company's platform addresses therapeutic targets across immune metabolism, lysosomal function, and mucosal defense, solute carrier cell transporters provide novel targets for immuno-oncology, inflammatory disorders, and neurological diseases, enabling companies to comprehensively address therapeutic targets across the vast member membrane protein family.
Contact Information
Website
www.jnanatx.com(Operating Subsidiary)
Corporate Office
- One Design Center Place
- Suite 19-400
- Boston, MA 02210
- United States
Corporate Office
- One Design Center Place
- Suite 19-400
- Boston, MA 02210
- United States
Jnana Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 08-Oct-2024 | $800M | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC (Series C1) | 15-Nov-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series B) | 18-Aug-2021 | $50M | $100M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 01-Jul-2017 | $50M | $50M | Completed | Startup |
Jnana Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B | ||||||||
| Series A-1 | 34,500,000 | $0.000100 | 3% | $0.5 | $0.5 | 1x | $0.5 | 10.44% |
| Series A | 32,950,000 | $0.000100 | 3% | $1 | $1 | 1x | $1 | 9.97% |
Jnana Therapeutics Comparisons
Industry
Financing
Details
Jnana Therapeutics Competitors (103)
One of Jnana Therapeutics’s 103 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Azitra | Formerly VC-backed | Branford, CT | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Circle Pharma | Venture Capital-Backed | South San Francisco, CA |
Jnana Therapeutics Patents
Jnana Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025217521-A1 | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist | Pending | 12-Apr-2024 | ||
| AU-2025254297-A1 | Treating chronic kidney disease with a combination of slc6a19 and sglt2 inhibitors | Pending | 12-Apr-2024 | ||
| WO-2025217520-A1 | Treating chronic kidney disease with a combination of slc6a19 and sglt2 inhibitors | Pending | 12-Apr-2024 | ||
| EP-4761732-A1 | Naphthyl-containing piperidine inhibitors of slc6a19 function | Pending | 17-Aug-2023 | ||
| WO-2025038949-A1 | Naphthyl-containing piperidine inhibitors of slc6a19 function | Inactive | 17-Aug-2023 | A61P3/10 |
Jnana Therapeutics Signals
Jnana Therapeutics Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Avalon Ventures | Venture Capital | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Pfizer Ventures | Corporate Venture Capital | Minority | ||
| Polaris Partners | Venture Capital | Minority |
Jnana Therapeutics FAQs
-
When was Jnana Therapeutics founded?
Jnana Therapeutics was founded in 2017.
-
Where is Jnana Therapeutics headquartered?
Jnana Therapeutics is headquartered in Boston, MA.
-
What is the size of Jnana Therapeutics?
Jnana Therapeutics has 90 total employees.
-
What industry is Jnana Therapeutics in?
Jnana Therapeutics’s primary industry is Drug Discovery.
-
Is Jnana Therapeutics a private or public company?
Jnana Therapeutics is a Private company.
-
What is the current valuation of Jnana Therapeutics?
The current valuation of Jnana Therapeutics is .
-
What is Jnana Therapeutics’s current revenue?
The current revenue for Jnana Therapeutics is .
-
How much funding has Jnana Therapeutics raised over time?
Jnana Therapeutics has raised $207M.
-
Who are Jnana Therapeutics’s investors?
AbbVie Ventures, Avalon Ventures, Bain Capital Life Sciences, Pfizer Ventures, and Polaris Partners are 5 of 7 investors who have invested in Jnana Therapeutics.
-
Who are Jnana Therapeutics’s competitors?
Adaptimmune Therapeutics, Azitra, CytomX Therapeutics, Virometix, and Circle Pharma are some of the 103 competitors of Jnana Therapeutics.
-
When was Jnana Therapeutics acquired?
Jnana Therapeutics was acquired on 08-Oct-2024.
-
Who acquired Jnana Therapeutics?
Jnana Therapeutics was acquired by Otsuka Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process